Aberdeen Group plc Purchases 88,784 Shares of Integer Holdings Corporation $ITGR

Aberdeen Group plc lifted its position in shares of Integer Holdings Corporation (NYSE:ITGR) by 38.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 319,229 shares of the medical equipment provider’s stock after purchasing an additional 88,784 shares during the quarter. Aberdeen Group plc owned about 0.91% of Integer worth $39,256,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ITGR. Wealth Enhancement Advisory Services LLC bought a new stake in Integer in the fourth quarter worth $208,000. Azzad Asset Management Inc. ADV boosted its holdings in Integer by 3.3% in the first quarter. Azzad Asset Management Inc. ADV now owns 12,544 shares of the medical equipment provider’s stock worth $1,480,000 after acquiring an additional 406 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in Integer in the first quarter worth $28,000. Vaughan Nelson Investment Management L.P. bought a new stake in Integer in the first quarter worth $33,337,000. Finally, QRG Capital Management Inc. boosted its holdings in Integer by 1.0% in the first quarter. QRG Capital Management Inc. now owns 37,306 shares of the medical equipment provider’s stock worth $4,402,000 after acquiring an additional 368 shares in the last quarter. 99.29% of the stock is owned by institutional investors.

Integer Stock Down 2.3%

ITGR stock opened at $100.99 on Monday. Integer Holdings Corporation has a fifty-two week low of $99.54 and a fifty-two week high of $146.36. The business’s 50-day moving average is $105.20 and its two-hundred day moving average is $113.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. The company has a market cap of $3.54 billion, a price-to-earnings ratio of 44.49, a P/E/G ratio of 0.80 and a beta of 0.97.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The firm had revenue of $476.00 million during the quarter, compared to the consensus estimate of $464.37 million. During the same period in the prior year, the company posted $1.30 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, analysts forecast that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Truist Financial dropped their target price on Integer from $145.00 to $137.00 and set a “buy” rating on the stock in a report on Friday, July 25th. Wall Street Zen raised Integer from a “hold” rating to a “buy” rating in a report on Saturday, August 30th. Wells Fargo & Company lowered their price target on Integer from $152.00 to $132.00 and set an “overweight” rating on the stock in a report on Friday, July 25th. Raymond James Financial dropped their price objective on Integer from $150.00 to $143.00 and set an “outperform” rating on the stock in a research report on Friday, July 25th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Integer in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Integer has an average rating of “Moderate Buy” and an average target price of $139.57.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.